. Author manuscript; available in PMC: 2021 Aug 1.

Published in final edited form as: Cancer Discov. 2021 Jan 15;11(2):266–281. doi: 10.1158/2159-8290.CD-20-0805

Table 2:

Examples of clinical trials testing combinations of immune modulatory agents with drugs capable of inducing inflammatory cell death

Drug combination	Trial examples (Cancer type)
Immune checkpoint inhibitor, chemotherapy −/+ radiation *addition of an angiogenesis inhibitor	NCT04238988, NCT03612791 (Cervical cancer) NCT04262687, NCT04262687, NCT04446091 (Colorectal cancer) NCT04444921 (Anal cancer) NCT03394885 (Ovarian cancer) NCT04282109, NCT03532737 (HNSCC) NCT04447612, NCT03984357 (Nasopharyngeal carcinoma) NCT04247165 (Pancreatic cancer) NCT02918162 (Gastric cancer) NCT04062708, NCT04137588, NCT04517526 (Non-small cell lung cancer) NCT04393506* (Oral squamous cell carcinoma) NCT03937830* (Hepatocellular carcinoma) NCT04472806* (Mucosal melanoma) NCT03409458 (Multiple solid tumors)
TLR agonist alone or in combination	NCT03734692 (Ovarian cancer) NCT02126579, NCT04364230, NCT04401995 (Melanoma) NCT02668770, NCT04270864, NCT04101357, NCT04116320, NCT02643303, NCT03416335 (Advanced malignancies) NCT04062721 (Colorectal cancer) NCT03906526 (HNSCC) NCT02452697 (Myeloid malignancies) NCT02927964, NCT01976585, NCT03410901 (Lymphomas) NCT04387071, NCT04050085 (Pancreatic cancer) NCT04338685 (Hepatocellular carcinoma or solid tumors with hepatic metastases)
SMAC mimetic, chemotherapy −/+ radiation	NCT03803774, NCT04459715, NCT02022098 (HNSCC)
SMAC mimetic, immune checkpoint inhibitor	NCT04122625, NCT03270176 (Advanced solid malignancies) NCT03871959 (Pancreatic cancer and colorectal adenocarcinoma)
Antibody drug-conjugates	NCT02980341 (HER3+ Breast cancer)
Inhibitor of extracellular ATP degradation, alone or in combination	NCT04336098, NCT04306900 (Advanced solid tumors) NCT03884556 (Advanced solid tumors and lymphoma)